Tempus Ai,Inc.(TEM) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for the core business increased by over 33% in 2025, with the acquisition of Ambry contributing to even higher growth [5][7] - Net revenue retention was reported at 126%, indicating strong customer loyalty and increased spending [7] - The company guided for $1.59 billion in revenue for 2026, aligning with long-term growth expectations of approximately 25% [7] Business Line Data and Key Metrics Changes - The diagnostics business in oncology experienced a unit growth of 29%, with a remarkable 56% quarter-over-quarter growth in minimal residual disease (MRD) testing [5][36] - The hereditary testing segment maintained a unit growth of 23% [5] - The data licensing business, referred to as Insights, grew by 69% in the quarter, with projections of around 40% growth for the upcoming quarter [6][7] Market Data and Key Metrics Changes - The company has established connections with over 5,500 hospitals and more than 8,500 oncologists, enhancing its market presence [12] - The total contract value for the data business exceeded $1.1 billion, indicating robust demand and growth potential [6][49] Company Strategy and Development Direction - The company aims to leverage its unique data advantages and AI capabilities to enhance diagnostic offerings and maintain a competitive edge in the healthcare sector [11][12] - The strategic focus includes expanding the comprehensive nature of testing solutions to meet the evolving needs of healthcare providers [61] - The company plans to continue investing in technology and AI to drive growth across its diagnostics and data businesses [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, citing strong demand for data products and a favorable market environment [49] - The company anticipates continued strong performance in oncology diagnostics, with expectations of high teens growth in hereditary testing [30][56] - Management highlighted the importance of proprietary data in training AI models, which is expected to enhance the company's offerings and market position [11][12] Other Important Information - The company is in the process of developing a foundation model for AI applications, with expectations of significant advancements in insights generation [28] - The average selling price (ASP) for tests was reported at approximately $1,640, with potential for increases driven by product mix changes and FDA approvals [22][23] Q&A Session Summary Question: Concerns about AI and market competition - Management emphasized the unique position of the company due to its proprietary data and established relationships with healthcare providers, which are difficult for competitors to replicate [11][12] Question: Strategic value of Paige Predict and ASP expectations - Management discussed the benefits of Paige Predict in enhancing diagnostic capabilities and provided insights on ASP growth expectations, indicating a potential increase to over $2,200 [16][22] Question: Update on foundation model development - Management confirmed that benchmarks for the foundation model have been met and that testing is ongoing, with expectations for significant value delivery across various data types [28] Question: Volume growth assumptions for oncology and hereditary testing - Management indicated strong growth in oncology diagnostics and moderate growth in hereditary testing, with expectations of high teens growth rates [30][56] Question: Insights on MRD testing and sales force effectiveness - Management highlighted the strong performance of MRD testing despite a constrained sales effort, indicating potential for significant growth once fully deployed [35][37] Question: Sales organization adjustments and investment priorities - Management confirmed no major changes to the sales organization but reiterated a commitment to leveraging technology and AI for growth [73][74]